Compare HXHX & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HXHX | BRTX |
|---|---|---|
| Founded | 2003 | 1997 |
| Country | China | United States |
| Employees | 85 | N/A |
| Industry | Trucking Freight/Courier Services | Managed Health Care |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 6.3M |
| IPO Year | N/A | 2015 |
| Metric | HXHX | BRTX |
|---|---|---|
| Price | $0.57 | $0.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 538.7K | ★ 1.1M |
| Earning Date | 05-20-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $298.39 |
| Revenue Next Year | N/A | $64.62 |
| P/E Ratio | $1.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.19 |
| 52 Week High | $2.11 | $2.04 |
| Indicator | HXHX | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.99 | 34.02 |
| Support Level | $0.48 | $0.19 |
| Resistance Level | $0.71 | $0.32 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 39.83 | 9.33 |
Haoxin Holdings Ltd is engaged in the logistics industry, including container provider of temperature-controlled truckload service and urban delivery services in China, freight forwarding, cold chain transportation and other businesses. The types of goods involved are all kinds of new energy materials that require low temperature, heat preservation, and constant temperature, electronic products, medicines, meat, fruits, vegetables and others.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.